Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Max India Limited operates as a holding company with investments in healthcare infrastructure through Max Healthcare Institute, one of India's largest private hospital chains with 17+ facilities across North and West India. The company's fundamentals show severe operational distress with negative margins across all levels, significant cash burn, and declining revenues, suggesting either a major restructuring event, asset write-downs, or transition period. The stock has declined 25.5% over the past year amid deteriorating financial performance.
As a holding company for hospital assets, Max India generates returns through ownership stakes in operating healthcare facilities that earn revenue from patient admissions, surgical procedures, and medical services. The business model typically relies on high bed occupancy rates (65-75% target), average revenue per occupied bed (ARPOB), and payor mix between cash-paying patients and insurance reimbursements. Current negative margins suggest extraordinary charges, restructuring costs, or operational challenges that have temporarily eliminated profitability. Healthcare infrastructure requires significant upfront capital but generates stable cash flows once facilities reach maturity, with pricing power derived from brand reputation, clinical outcomes, and location advantages in metro markets.
Bed occupancy rates and average revenue per occupied bed (ARPOB) trends across hospital network
New facility openings, brownfield expansions, or acquisition announcements that expand geographic footprint
Payor mix shifts between cash patients (higher margins) versus insurance/government schemes (lower reimbursement rates)
Regulatory changes affecting hospital reimbursement rates, medical device pricing, or healthcare insurance penetration in India
Resolution of current financial distress - asset sales, debt restructuring, or capital infusions
Government healthcare policy shifts including price controls on medical procedures, drug pricing regulations, or expansion of public healthcare infrastructure that competes with private hospitals
Regulatory changes to hospital accreditation standards, medical staff licensing, or insurance reimbursement frameworks that increase compliance costs or reduce revenue capture
Technology disruption through telemedicine platforms and diagnostic AI reducing demand for physical hospital visits for certain service lines
Intense competition from established hospital chains (Apollo Hospitals, Fortis Healthcare) and new entrants backed by private equity expanding capacity in key metro markets
Pricing pressure from insurance companies and TPAs negotiating lower reimbursement rates as they consolidate purchasing power
Difficulty attracting and retaining specialized medical talent in competitive markets, affecting clinical reputation and patient volumes
Critical liquidity risk with $1.5B negative free cash flow and ongoing cash burn requiring immediate capital infusion or asset monetization to avoid covenant breaches
Debt service obligations on 0.44x debt/equity with negative EBITDA creating refinancing risk and potential distressed sale scenarios
Asset impairment risk if hospital properties or goodwill require write-downs, further eroding equity value and triggering debt covenant violations
moderate - Healthcare demand is relatively inelastic for emergency and critical care, but elective procedures and premium services show cyclical sensitivity. Rising disposable incomes in India's middle class drive healthcare spending and insurance adoption. Current negative margins suggest company-specific issues override macro factors, but economic growth affects patient volumes for non-urgent procedures and ability to sustain premium pricing in competitive metro markets.
Rising interest rates negatively impact the business through higher financing costs on the 0.44x debt/equity position and increased cost of capital for expansion projects. Healthcare infrastructure requires long-term capital commitments with 7-10 year payback periods, making projects less attractive as discount rates rise. Additionally, higher rates can pressure consumer spending on elective healthcare and reduce private equity valuations for potential exit scenarios.
Moderate credit exposure through patient payment cycles and insurance reimbursement timing. Corporate health insurance penetration and third-party administrator (TPA) payment reliability affect working capital. Current 2.03x current ratio suggests adequate short-term liquidity, but negative operating cash flow of $1.1B indicates collections or operational issues. Credit market conditions affect ability to refinance existing debt or raise capital for turnaround.
Currently attracts distressed/special situations investors and turnaround specialists given severe financial distress. Historically would attract growth investors focused on India's healthcare infrastructure buildout and rising middle-class healthcare consumption. The -25.5% one-year return and negative margins have likely driven out institutional long-only investors until profitability path becomes clear. Requires high risk tolerance and deep healthcare sector expertise.
high - Stock has declined 20% in past 3 months with significant fundamental uncertainty. Healthcare holding companies typically show moderate volatility, but current financial distress, negative cash flows, and lack of earnings visibility create elevated volatility. Beta likely exceeds 1.5x given company-specific execution risks layered on top of emerging market healthcare sector volatility.
